Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Table 1 Baseline demography and disease characteristics

	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Total
	(n = 381)	(n = 105)	(n = 486)
Female, n (%)	318 (83.5)	86 (81.9)	404 (83.1)
Age in years, mean (SD)	53.5 (11.2)	49.3 (11.7)	52.6 (11.4)
Disease duration in years, mean (range)	7.8 (0.4–38.0)	6.1 (0.4–45.0)	7.4 (0.4–45.0)
Tender joint count^a, n	16.1	17.0	16.3
Swollen joint count^a, n	13.4	14.3	13.6
HAQ-DI^b score	1.23	1.22	1.23
DAS28-4(ESR) score	6.0	6.1	6.0
DAS28-3(CRP) score	5.0	5.2	5.1
ESR, mm/h	50.7	47.7	50.1
CRP, mg/L	24.1	27.4	24.9
Concomitant methotrexate, n (%)	196 (51.4)	26 (24.8)	222 (45.7)
Concomitant systemic corticosteroids, n (%)	256 (67.2)	80 (76.2)	336 (69.1)

Data are mean values except where indicated. Baseline values were those of the index study
^aScale 0–68 (tender/painful joints) and 0–66 (swollen joints); higher values indicate greater levels of disease activity
^bScale: 0–3; higher values indicate reduced physical function
BID twice daily, CRP C-reactive protein, DAS Disease Activity Score, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, SD standard deviation